Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)

Asan Medical Center

Status: Completed

Conditions: Bone Marrow Transplantation

Study type: Observational

Funder types: Other

Identifiers

NCT02081716

2014-0103

Details and patient eligibility

About

CMV is one of the most important opportunistic infection in transplant recipients. In South Korea, more than 95% of adults reveal sero-positivity for CMV IgG. Until now, sero-positivity for CMV IgG before bone marrow organ transplantation is a laboratory test of choice to stratify the risk of CMV reactivation after solid organ transplantation. Theoretically, CMV-specific cell-mediate immune response before and after bone marrow transplantation will further categorize the patients into high or low risk of CMV development after bone marrow transplantation. The investigators thus evaluate the usefulness of CMV-specific ELISPOT assay in bone marrow transplant candidates to predict the development of CMV infection after transplantation.

Full description

We will evaluate whether CMV-specific cell-mediated immune response before transplant, 1 month, 3 months, and 6 months after transplantation will predict CMV infection after bone marrow transplantation.

Enrollment: 88 patients

Sex: All

Ages: 16 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 16 or more
• agree with written informed consent

Exclusion criteria

• no exclusion criteria

Trial design

88 participants in 2 patient groups

high CMV ELISPOT results

Description:

high spot counts in ELISPOT

low CMV ELISPOT results

Description:

low spot counts in ELISPOT